Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMLYI4Z)

• Drug Name: SAR443765 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Asthma	CA23	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMLYI4Z

Molecule-Related Drug Atlas

Drug(s) Targeting Interleukin-13 (IL13)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tralokinumab	DM6ENSJ	Atopic dermatitis	EA80	Approved	[3]
Lebrikizumab	DMQP0X5	Severe asthma	CA23	Phase 3	[4]
Dexpramipexole	DM6KXAU	Eosinophilic asthma	CB02.0	Phase 3	[5]
Cendakimab	DM9LSBJ	Eosinophilic esophagitis	DA24.1	Phase 3	[6]
SAR-156597	DMUICJD	Idiopathic pulmonary fibrosis	CB03.4	Phase 2	[7]
PEGylated pitrakinra	DMBPJ9U	Asthma	CA23	Phase 2	[4]
Romilkimab	DMYEZ5J	Idiopathic pulmonary fibrosis	CB03.4	Phase 2	[8]
QAX-576	DMUWFI7	Allergic rhinitis	CA08.0	Phase 2	[9]
Anrukinzumab	DMTG2O0	Asthma	CA23	Phase 2	[10]
Dectrekumab	DM1H7UK	Idiopathic pulmonary fibrosis	CB03.4	Phase 2	[9]

Drug(s) Targeting Thymic stromal lymphopoietin (TSLP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tezepelumab	DM9R5J6	Severe asthma	CA23	Approved	[11]
A378	DMUWRTB	Asthma	CA23	IND submitted	[12]
MEDI9929	DMGD1YP	Asthma	CA23	Phase 2	[13]
CSJ117	DMZJUV6	Asthma	CA23	Phase 2	[14]
AMG 104	DM3XC31	Asthma	CA23	Phase 1	[15]
AZD8630	DMMUF0O	Asthma	CA23	Phase 1	[16]
PF-07275315	DMHRVUY	Atopic dermatitis	EA80	Phase 1	[17]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin-13 (IL13)	TT0GVCH	IL13_HUMAN	Not Available	[2]
Thymic stromal lymphopoietin (TSLP)	TTHMW3T	TSLP_HUMAN	Not Available	[2]

References

• [1] ClinicalTrials.gov (NCT05366764) A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of SAR443765 in Healthy Adult Participants and of a Single Dose of SAR443765 in Participants With Mild-to-moderate Asthma. U.S.National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of Sanofi
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72.
• [5] Therapeutic strategies for eosinophilic dermatoses. Curr Opin Pharmacol. 2019 Jun;46:29-33.
• [6] Biologics in eosinophilic gastrointestinal diseases. Ann Allergy Asthma Immunol. 2023 Jan;130(1):21-27.
• [7] Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
• [8] A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis. Ann Rheum Dis. 2020 Dec;79(12):1600-1607.
• [9] Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. J Allergy Clin Immunol. 2015 Feb;135(2):500-7.
• [10] Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study.Gut.2015 Jun;64(6):894-900.
• [11] Tezepelumab in Adults with Uncontrolled Asthma. N Engl J Med. 2017 Sep 7;377(10):936-946.
• [12] Clinical pipeline report, company report or official report of Klus Pharma
• [13] Human immunoglobulin G2Lambda monoclonal antibody directed against thymic stromal lymphopoietin (MEDI9929). European medicines agency science medicines health (EMEA-001613-PIP01-14). European Union. 2015.
• [14] TSLP Inhibitors for Asthma: Current Status and Future Prospects. Drugs. 2020 Apr;80(5):449-458.
• [15] Clinical pipeline report, company report or official report of Amgen
• [16] Clinical pipeline report, company report or official report of AstraZeneca
• [17] Clinical pipeline report, company report or official report of Pfizer